Breaking Science in Gastrointestinal Cancers with Francesco Sclafani – ESMO

ESMO (European Society for Medical Oncology) shared a post on LinkedIn:

”For ESMO members: Breaking Science in Gastrointestinal Cancers.

Francesco Sclafani shares insights on his presentation about Neoadjuvant regorafenib, nivolumab and short-course radiotherapy for stage II-III rectal cancer.

Watch this video and others from this series on OncologyPRO now.”

Source: ESMO/LinkedIn

The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up. It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.